Somewhere between the 1950s and today, the average human lifespan in wealthy countries extended by roughly 25 years. Most people attribute that to better food, cleaner water, or exercise habits. The real driver was something far more specific: a relentless sequence of targeted medical discoveries that each, one by one, dismantled conditions that used to kill reliably and routinely.
That sequence hasn’t stopped. In the last two years, researchers have produced a cluster of advances that are genuinely distinct from the steady incremental progress that fills most scientific journals. An HIV injection that works twice a year and showed 100% efficacy in one trial. A diabetes drug that also prevents heart attacks. A gene therapy custom-built for a single infant. Several are FDA-approved, in clinics, and changing what patients can realistically expect.
What follows is a detailed account of those breakthroughs – what they are, how they work, and what the current evidence actually shows. No breathless promise, no vague “scientists say.” Just the specific findings and what they mean for people who will encounter these treatments as patients, family members, or curious readers trying to understand where medicine actually stands in 2026.
GLP-1 Drugs: The Weight-Loss Medications That Also Protect the Heart
Semaglutide and tirzepatide became household names as weight-loss drugs. Their cardiac effects are turning out to be just as significant. A research team at Mass General Brigham found that both medications reduced the risk of heart attack, stroke, and death from any cause, with results published in Nature Medicine and presented at the American Heart Association Scientific Sessions 2025.
The study drew on national claims databases to compare cardiovascular outcomes across nearly one million adults taking tirzepatide, semaglutide, or other diabetes medications. That scale makes the findings unusually robust. Real-world data from a million patients is harder to dismiss than a smaller clinical trial of carefully selected participants.
The cardiovascular protection appears to extend beyond diabetes management. According to the Mass General Brigham press release, first author Nils Krüger, MD, a research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics, noted: “Both drugs show strong cardioprotective effects. Our data also indicate that these benefits occur early, suggesting that their protective mechanisms go beyond weight loss alone.” A separate Mass General Brigham analysis found the drugs were associated with a greater than 40% reduction in heart failure hospitalization or all-cause mortality compared with sitagliptin, a standard diabetes medication with no known cardiac benefit. For patients managing type 2 diabetes, both drugs now represent something beyond glucose control – they appear to function as cardiovascular protection at the same time.
A 2026 review covering more than 90,000 patients reinforced those findings, with GLP-1 drugs significantly lowering the combined risk of heart attack, stroke, heart failure, and premature death. The consistency across datasets of vastly different sizes makes the signal difficult to ignore.
A Twice-Yearly HIV Injection That Approached 100% Efficacy
For four decades, preventing HIV has meant taking a pill every single day. The adherence problem is real: daily pill regimens fail quietly, through missed doses, disrupted routines, or the psychological burden of a daily reminder of risk. On June 18, 2025, the FDA approved twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP), making it the longest-acting HIV prevention method available.
The trial data behind the approval was striking. The PURPOSE 1 trial enrolled 5,000 sexually active women across Uganda and South Africa, with researchers publishing results in the New England Journal of Medicine in July 2024, finding lenacapavir was 100% effective, with zero infections across 2,138 participants. The PURPOSE 2 trial, which enrolled men and gender-diverse individuals across multiple countries and was also published in the New England Journal of Medicine in November 2024, showed a 96% reduction in HIV incidence compared to background infection rates in those communities.
Despite progress in HIV prevention, global targets remain unmet, with over 1.3 million new infections annually, driven by adherence challenges, stigma, and daily pill fatigue. A twice-yearly injection addresses all three simultaneously. The World Health Organization welcomed the FDA approval, noting it followed the promising 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated safety and efficacy across diverse populations and settings.
The drug, sold under the brand name Yeztugo, is being launched into a system where access to life-saving treatments remains deeply unequal, with lenacapavir currently priced at over $28,000 annually in the United States, raising real questions about who will actually be able to use it. Gilead Sciences has filed for approval in multiple countries, including Brazil, Canada, South Africa, and Australia, with an accelerated review pending at the European Medicines Agency.
Alzheimer’s: The First Drug That Actually Slows the Disease
For generations, Alzheimer’s disease had no treatment that touched its underlying biology. Drugs could soften some symptoms temporarily. None of them slowed the disease itself. That changed in 2023 when lecanemab (brand name Leqembi) became the first therapy to receive FDA traditional approval for actually modifying Alzheimer’s progression in early-stage patients. The question since then has been whether the benefit holds up over time.
Results from the Clarity AD open-label extension, presented at the Clinical Trials on Alzheimer’s Disease conference in late 2025 and published in Alzheimer’s & Dementia, show that lecanemab slowed clinical decline by 1.75 points on the Clinical Dementia Rating – Sum of Boxes scale. The benefit increased over time, with a reduction of 1.01 points at three years rising to 1.75 points at four years. That growing effect is meaningful – it suggests the drug isn’t just producing a temporary plateau, but continuing to diverge from the untreated decline trajectory as treatment continues.
Separate modeling data presented at the Clinical Trials on Alzheimer’s Disease conference in 2025 suggest that early, continued treatment with lecanemab may delay disease progression by up to 8.3 years. To put that number in context: the drug doesn’t stop Alzheimer’s. It doesn’t reverse existing damage. But delaying progression by years, for a disease where every year of function preserved matters enormously to patients and families, is a fundamentally different category of outcome than symptom management.
Lecanemab is an amyloid-beta monoclonal antibody that targets and clears toxic protofibrils – the soluble form of the protein believed to be the most damaging – and reduces amyloid plaques in the brain. Patients considering it should know that it’s approved only for early-stage Alzheimer’s, requires regular infusions and brain imaging to monitor for side effects, and is not a cure.
You can find further context on Alzheimer’s research and experimental approaches in this related article from The Hearty Soul: Alzheimer’s Patient Gets Back Speech, Continence and Memory After Experimental Drug
CRISPR Gene Editing: From Mice to a Single Infant
CRISPR gene editing has been a laboratory tool for over a decade. Its clinical translation has been slower than the hype suggested, largely because delivering the gene-editing machinery safely into living human cells is genuinely difficult. In February 2025, that barrier was cleared in a way that won’t be forgotten.
A team of physician-scientists at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine, led by Drs. Rebecca Ahrens-Nicklas and Kiran Musunuru, used a personalized in vivo (inside the living body) base-editing therapy to treat an infant known as KJ, who had been diagnosed with carbamoyl phosphate synthetase I deficiency, a rare metabolic disorder with a 50% mortality rate in infancy. The therapy used lipid nanoparticles – tiny fat-based spheres – to carry the gene-editing instructions directly into the child’s liver cells, correcting the specific mutation unique to that patient. Results were published in the New England Journal of Medicine on May 15, 2025, with NIH providing research support throughout the development process.
The lipid nanoparticle delivery method is central to why this worked. These carriers are attractive as non-viral delivery vehicles due to their low immunogenicity and high delivery efficiency – meaning the body is less likely to mount an immune attack on the therapy itself, compared to earlier viral delivery approaches. KJ’s case represented the first time a gene therapy was custom-designed specifically for one patient’s exact mutation rather than a general disease category, pointing toward what individualized medicine may eventually look like.
CAR-T Cell Therapy Expands Its Reach
CAR-T therapy works by removing a patient’s T cells (the immune system’s attack cells), engineering them in a laboratory to recognize specific cancer proteins, and infusing them back into the patient’s body. Since 2017, this approach has produced remarkable results in blood cancers. The challenge has always been extending it to solid tumors, where the environment around cancer cells actively suppresses immune responses.
CAR-T found its first clinical applications in hematological cancers resistant to standard treatments – conditions like acute lymphoblastic leukemia and diffuse large B-cell lymphoma. In 2017, the FDA approved the first CAR-T product, tisagenlecleucel, for children and young adults with relapsed leukemia. The field has since expanded, and 2025 brought two meaningful structural changes.
On June 26, 2025, the FDA eliminated REMS requirements for all approved CD19- and BCMA-directed CAR-T therapies – a bureaucratic barrier that previously required patients to receive treatment only at specially certified hospitals. That removal expands the number of facilities that can legally administer these therapies, bringing them within practical reach of patients who don’t live near major cancer centers. At the same time, the first CAR-T therapy approved specifically for a solid tumor was cleared in China for gastric (stomach) cancer, marking the first time the approach has demonstrated clinically meaningful efficacy outside blood cancers in a regulatory context. Researchers publishing in Cell Reports Medicine are actively mapping how recent clinical trials in solid tumors succeeded where earlier ones failed.
mRNA Technology Moves Beyond COVID-19
The mRNA vaccine platform developed for COVID-19 is now being applied to diseases far outside its original use. The core technology works by giving cells temporary instructions to produce a specific protein – in COVID’s case, the spike protein – which then trains the immune system to recognize and fight the real pathogen. The same mechanism can theoretically be pointed at almost any target the immune system can be trained to attack.
Researchers are now using it for cancer, where the approach involves programming the vaccine to target proteins specific to a patient’s own tumor – proteins that emerged from the cancer’s mutations and don’t appear in healthy tissue. Personalized mRNA cancer vaccines are in active clinical trials, with several targeting melanoma, lung, and pancreatic cancers.
The platform is also being directed at influenza. In May 2025, HHS and NIH announced a next-generation universal vaccine platform, with flu vaccine clinical trials scheduled to begin in 2026 and FDA approval targeted for 2029. According to AJMC’s coverage of the announcement, a universal flu vaccine has been a decades-long goal in infectious disease: current seasonal flu shots require annual reformulation because the virus mutates rapidly, and they remain only partially effective. An mRNA-based universal flu vaccine that produces broader, more durable immunity would represent a significant upgrade to one of the most widely deployed preventive interventions in public health.
Read More: Kids With Deadliest Brain Cancers Survive Years After Breakthrough Cell Therapy
What This Means for You
Medicine doesn’t deliver revolutions on a schedule. What it does deliver, occasionally, is a cluster of genuine advances in a short window – and the evidence suggests 2024 to 2026 has been one of those windows. A twice-yearly HIV injection. An Alzheimer’s drug that buys years, not weeks. Gene therapy built for a single patient’s single mutation. Diabetes drugs that turn out to also protect the heart.
None of these are cure-alls. Lecanemab slows Alzheimer’s – it doesn’t stop it, and it works only in early-stage patients who are correctly diagnosed. CAR-T therapy for solid tumors remains in its early stages outside of specific cancer types. Lenacapavir’s $28,000 annual price tag will limit access for most of the world unless pricing changes. CRISPR therapies are still highly experimental and available only through research programs. The right response to this moment isn’t uncritical optimism – it’s knowing which questions to ask your doctor. If you or a family member is managing early Alzheimer’s, ask specifically whether lecanemab is appropriate for your stage. If you’re at elevated risk for HIV, ask about lenacapavir by name. If you have type 2 diabetes and cardiovascular risk, ask whether semaglutide or tirzepatide might be right for both concerns. The treatments now exist. The gap between “exists” and “in your hands” is often just a conversation.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.